Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.48
Bid: 18.20
Ask: 18.50
Change: -0.37 (-1.96%)
Spread: 0.30 (1.648%)
Open: 18.48
High: 18.48
Low: 18.40
Prev. Close: 18.85
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Receipt of General Meeting Requisition Notice

28 Jun 2023 07:00

RNS Number : 1198E
Nanoco Group PLC
28 June 2023
 

28 June 2023

NANOCO GROUP PLC

("Nanoco", the "Company" or the "Group")

 

Receipt of General Meeting Requisition Notice

 

Nanoco notes that on 27 June 2023 it received a letter and accompanying notice from Aurora Nominees Limited and Securities Services Nominees Limited seeking, on behalf of holders of approximately 5.02% of the voting rights of the Company (together the "Requisitionists"), to requisition a general meeting ("GM") of the Company under section 303 of the Companies Act 2006 (the "Requisition").

The Requisition proposes the removal of all of the Group's current directors, including its Chairman, Chief Executive Officer, Chief Finance Officer and Chief Technology Officer (the co-founder of Nanoco and inventor of Nanoco's key quantum dot scale-up technology) with effect from the requisitioned GM and their replacement by new directors proposed by the Requisitionists. Should the resolutions to be proposed at the GM be successful, these new directors proposed by the Requisitionists would thereafter comprise the entire Board.

Background to the Requisition

The Requisition follows the receipt of two letters from Mr Hamoodi which the Company responded to by means of RNS announcements (including a link to a letter sent to Mr Hamoodi) issued on 27 March 2023 and 19 May 2023, respectively. Nanoco's announcements emphatically rejected Mr Hamoodi's speculative concerns contained in his letters about certain actions and activities involving Nanoco, as well as a proposal that certain directors of Nanoco be replaced by his own nominees. The Company confirmed that the Directors of Nanoco have no intention of stepping down from the Board and are confident that the Board's actions and statements over the period of the Samsung litigation were in line with its corporate governance duties, obligations and standards.

A copy of Nanoco's letter to Mr Hamoodi is available here:

http://www.rns-pdf.londonstockexchange.com/rns/0649A_1-2023-5-19.pdf.

Response to the Requisition

The Board is in the process of reviewing the content and validity of the Requisition with its advisers and will make an announcement regarding the convening of a general meeting in due course.

In line with the announcement issued on 19 May, the Board is firmly of the view that the board changes proposed by Mr Hamoodi are not in the best interests of the Company or its shareholders.

The Board believes that the blend of skills and capabilities of its members has been demonstrated both in the transformative outcome achieved in the Samsung settlement and the progress made with the organic business.

As outlined in the circular regarding the proposed capital reduction to facilitate future returns to shareholders, published on 20 June 2023 (the "Circular"), the Board is confident in the near-term opportunities for commercial production of sensing materials. The Board has highlighted the current interest in the Group's display materials following the successful IP litigation as well as the growing display market for CFQD® cadmium free quantum dots. Furthermore, the Circular outlined Nanoco's intention to:

· initiate a return of between £33 million and £40 million (or approximately 10 pence to 12 pence per share) using the second tranche of the proceeds of the Samsung litigation (net $71.75 million after withholding tax) which is expected to be received during February 2024; and

 

· retain approximately £20 million of cash (following the return to shareholders) to invest in R&D and commercial activities, a proactive IP licensing programme, payment of debt obligations, and to provide working capital through to the self-financing position that is expected to be achieved during 2025.

Mr Hamoodi's proposals to change the entire board would be damaging and disruptive to the business. The Board believes that, if successful, they would result in the departure of key employees who are critical to Nanoco's future success, including but not limited to, Dr Nigel Pickett, Nanoco's Chief Technology Officer, co-founder and named inventor on many of the Company's core patents.

Christopher Richards, Non-Executive Chairman of Nanoco, said

"We continue to emphatically reject Mr Hamoodi's proposals to change the entirety of the board at such a key point in Nanoco's evolution. The Board welcomes scrutiny but his selective interpretation of the past, significant factual errors, and speculative concerns take a number of events out of context to create a misleading narrative.

"The proposed Board changes are not in the best interests of the Company or its shareholders. Nanoco is at an exciting inflection point, with the litigation proceeds fully underpinning our organic business which has significant growth opportunities, as well as offering an attractive potential return of capital to shareholders.

"Mr Hamoodi's proposals would be damaging and disruptive to Nanoco's future prospects and likely result in an exodus of key talent from the business."

 

- Ends -

For further information, please contact:

Nanoco Group PLC: +44(0)1928761404

Dr Christopher Richards, Non-Executive Chairman

Brian Tenner, CEO

Liam Gray, CFO & Company Secretary

 

Peel Hunt (Joint Corporate Broker): +44 (0) 20 7418 8900

Paul Gillam

James Smith

 

Turner Pope Investments (Joint Corporate Broker): +44 (0) 20 3657 0050

Andrew Thacker

James Pope

 

MHP: +44 (0) 203 128 8570

Reg Hoare

Matthew Taylor

Christian Harte

nanoco@mhpgroup.com

 

 

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots and other nano-materials. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display, Sensor and Electronics markets. An interesting property of quantum dots is size-tunable absorption spectrum. Nanoco's HEATWAVE™ quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectrum, rendering them useful for applications including image sensors. Another interesting property of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco was founded in 2001 and is headquartered in Runcorn, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information, please visit: www.nanocotechnologies.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUBOARONUNUUR
Date   Source Headline
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany
19th Aug 20228:21 amRNSLitigation Update – Pre-Trial Conference
18th Aug 20224:10 pmRNSDirector/PDMR Shareholding
16th Aug 20227:00 amRNSTrading Update
28th Jul 202210:42 amRNSHolding(s) in Company
13th Jul 20222:03 pmRNSReplacement - Director/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
13th Jul 202212:00 pmRNSDirector/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
30th Jun 20227:00 amRNSTotal Voting Rights
29th Jun 20227:00 amRNSChange of Auditor
23rd Jun 20223:48 pmRNSDirector/PDMR Shareholding
22nd Jun 20222:25 pmRNSHolding(s) in Company
21st Jun 20223:36 pmRNSDirector/PDMR Shareholding
21st Jun 20229:06 amRNSReplacement: Director/PDMR Shareholding
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
17th Jun 20224:36 pmRNSPrice Monitoring Extension
17th Jun 202210:45 amRNSHolding(s) in Company
14th Jun 20229:42 amRNSHolding(s) in Company
9th Jun 20227:00 amRNSBlock listing Six-monthly Return
8th Jun 202212:00 pmRNSResults of Fundraise
8th Jun 20227:00 amRNSFundraise significantly over-subscribed
7th Jun 20225:16 pmRNSReplacement: Litigation Update
7th Jun 20224:55 pmRNSLitigation Update
6th Jun 20227:02 amRNSTrading Update & Proposed Fundraise
6th Jun 20227:00 amRNSMajor Work Package for European Customer
23rd May 20225:00 pmRNSHolding(s) in Company
17th May 20227:02 amRNSLitigation Update
13th May 202212:15 pmRNSHolding(s) in Company
13th Apr 20222:49 pmRNSHolding(s) in Company
12th Apr 20227:00 amRNSInterim Results
17th Mar 20227:00 amRNSAdditional Work Package for European Customer
15th Mar 20227:00 amRNSNotice of Interim Results
4th Feb 20223:14 pmRNSHolding(s) in Company
31st Jan 20227:00 amRNSTotal Voting Rights
9th Dec 20217:00 amRNSBlock listing Six-Monthly Return
2nd Dec 20217:18 amRNSBlock Listing Application
1st Dec 202112:30 pmRNSDirector/PDMR Shareholding
1st Dec 202112:28 pmRNSAnnual General Meeting – Voting Results
30th Nov 20217:00 amRNSAGM Statement
18th Nov 20211:13 pmRNSDirector/PDMR Shareholding
9th Nov 20217:11 amRNSDirector/PDMR Shareholding
8th Nov 20217:00 amRNSDirector Appointment
5th Nov 202111:25 amRNSAdditional Work Package for European Customer
4th Nov 20216:20 pmRNSNotice of AGM
3rd Nov 20217:00 amRNSPreliminary Results
18th Oct 20216:10 pmRNSChange to final results announcement date
13th Oct 20219:30 amRNSPresentation via Investor Meet Company
8th Oct 20211:48 pmRNSNotice of Results
19th Aug 20217:00 amRNSNon-Executive Director Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.